Latest Car T News

Foresta Group Holdings has received allowance from the USPTO for its US patent application covering its proprietary rosin and terpene production process, expected to protect its technology until at least 2041.

Imugene reports a second complete response in its Phase 1b trial of azer-cel combined with BTK inhibitors, including the first patient with Mantle Cell Lymphoma who had failed prior BTKi therapy.

AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.

Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.

2 Cheap Cars Group maintained steady revenue and profit in FY26 despite softer vehicle sales and regulatory headwinds, driven by strong EV demand and record finance and insurance penetration.

INOVIQ Limited’s CAR-exosome platform demonstrated potent tumour-killing activity in ovarian cancer cell lines, eliminating up to 90% of cancer cells within 48 hours and reinforcing its potential against hard-to-treat solid tumours.

Baby Bunting anticipates FY26 pro forma NPAT between $16 million and $17 million, marking a 32% to 40% increase from FY25, despite weaker sales in the fourth quarter. The retailer’s Store of the Future refurbishments and online channels continue to drive growth amid a challenging consumer backdrop.

Peter Warren Automotive has withdrawn its initial ACCC application for the Wakeling Automotive acquisition, opting to submit a fresh Phase 1 proposal with remedies to secure regulatory approval.

Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.

The ACCC has moved Peter Warren Automotive’s proposed acquisition of 30 Wakeling Automotive dealerships to a Phase 2 review, citing risks of reduced competition in Sydney’s Macarthur region.

The ACCC has moved Peter Warren Automotive’s acquisition of Wakeling Automotive’s 30 dealership sites into a Phase 2 review amid concerns it could dominate Sydney’s Macarthur region new car market, controlling 25 of 33 dealerships locally.